Yu Sunakawa, MD, PhD, St. Marianna University School of Medicine, Kawasaki, Japan, presents data from a survival analyses of the Phase II DEEPER trial (NCT02515734) of cetuximab versus bevacizumab in combination with modified (m)-FOLFOXIRI in patients with previously untreated metastatic colorectal (mCRC) with RAS wild-type tumors. Addition of cetuximab resulted in longer progression-free survival (PFS) in patients with left-sided tumors, compared to the PARADIGM trial (NCT02394795), where PFS was similar in the panitumumab and bevacizumab arms. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
